Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameModern Chi Med
Stock Code01643
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities主要從事生產中成藥,提供中老年人士使用的非處方藥及處方藥,擁有59種中成藥產品,主要產品包括補腎填精丸、氣血雙補丸、山玫膠囊、金匱腎氣丸、心安膠囊、加味逍遙丸、護肝片、加味藿香正氣丸及清瘟解毒丸。
Listing Date2021-01-15
Listing Rules EraOld Rules
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)河北省承德市津圍公路88號
Business Address (Hong Kong)香港 皇后大道東183號 合和中心54樓
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitecdysjdyy.com
Share Registrar卓佳证券登记有限公司 (Tricor Investor Services Limited)
Registrar Contact(852)2980 1333
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 1.18 / shares
Offer Price RangeFinal offer price only, no range
Lot Size3,000 shares
Entry ThresholdHK$ 3,540
Par ValueRMB 0.01 / shares
Offer Period2020-12-31 to 2021-01-07
Global Offering Shares150,000,000 shares
HK Public Offer Shares (Initial)15,000,000 shares (10.0%)
Public Offer Lots (Initial)5,000lots (Pool A2,500lots,Pool B2,500lots)
International Placing Shares (Initial)135,000,000 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO600,000,000 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone ShareNo cornerstone investors
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 177,000,000

Subscription Tiers

Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.

Pool A
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1 lots 3,000 HK$ 3,540
2 lots 6,000 HK$ 7,080
3 lots 9,000 HK$ 10,620
4 lots 12,000 HK$ 14,160
5 lots 15,000 HK$ 17,700
6 lots 18,000 HK$ 21,240
7 lots 21,000 HK$ 24,780
8 lots 24,000 HK$ 28,320
9 lots 27,000 HK$ 31,860
10 lots 30,000 HK$ 35,400
15 lots 45,000 HK$ 53,100
20 lots 60,000 HK$ 70,800
25 lots 75,000 HK$ 88,500
30 lots 90,000 HK$ 106,200
35 lots 105,000 HK$ 123,900
40 lots 120,000 HK$ 141,600
45 lots 135,000 HK$ 159,300
50 lots 150,000 HK$ 177,000
100 lots 300,000 HK$ 354,000
150 lots 450,000 HK$ 531,000
200 lots 600,000 HK$ 708,000
250 lots 750,000 HK$ 885,000
300 lots 900,000 HK$ 1,062,000
350 lots 1,050,000 HK$ 1,239,000
400 lots 1,200,000 HK$ 1,416,000
450 lots 1,350,000 HK$ 1,593,000
500 lots 1,500,000 HK$ 1,770,000
750 lots 2,250,000 HK$ 2,655,000
1,000 lots 3,000,000 HK$ 3,540,000
1,250 lots 3,750,000 HK$ 4,425,000
Pool B
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1,500 lots 4,500,000 HK$ 5,310,000
1,750 lots 5,250,000 HK$ 6,195,000
2,250 lots 6,750,000 HK$ 7,965,000
2,500 lots 7,500,000 HK$ 8,850,000

Stock Connect Inclusion Analysis

26Q4 Regular Review
Inclusion Pathway Regular Path
Avg Daily HK Mkt Cap HK$ 833.4M
Est. Threshold HK$ 9.71B
Analysis Result HK market cap below threshold, need +1066%

Valuation & Financials

Market Cap (at Offer Price)HK$ 708,000,000
Pre-IPO Valuation (Last Round)Not disclosed
P/E RatioNot disclosed
Profit/Loss Status盈利約人民幣46.2百萬元
Period-End Cash BalanceTo be extracted
Listing Expenses~HK$ 60,000,000
Listing Expenses / Funds Raised~33.9%
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 RMB
Income Statement
Item 201720182019
Revenue 106,466173,512218,767
Cost of sales -62,039-99,855-119,698
Gross profit 44,42773,65799,069
Other income and gains, net 452770174
Selling and distribution expenses -4,270-4,938-8,105
Administrative expenses -4,648-4,982-14,124
Operating profit 35,96164,50765,256
Net finance costs -1,19100
Profit before tax 34,77064,50765,256
Income tax expense -8,889-16,270-19,019
Profit for the year 25,88148,23746,237
Balance Sheet
Item 2017201820192020-09
Cash and cash equivalents 12,86589,94035,891
Trade and bills receivables 32,85728,68027,737
Inventories 53,55339,01140,933
Total current assets 99,275157,631104,561
Total assets 116,243173,014123,110
Total current liabilities 40,66149,19554,256
Total liabilities 40,66149,19554,256
Total equity 75,582123,81968,854
Equity attributable to owners 75,582123,81968,854
Interest-bearing borrowings 005,0005,000
Cash Flow Statement
Item 2017201820192020-09
Net cash from operating activities -25,45577,11240,240
Net cash from investing activities -1,542-37-1,207
Net cash from financing activities -41,9890-92,943
Net increase in cash -68,98677,075-53,910
Depreciation of PP&E 1,8021,7161,5501,343
Purchase of PP&E -1,933-172-2,619-446
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 1.26
First Day OpenHK$ 1.17
First Day Change6.78%
First Day Volume83169000.0
First Day Turnover103949000.0
Use of Proceeds
1、約44.0%或51.7百萬港元將用于提高及擴大產能,進一步生產我們的主要膠囊處方藥; 2、約16.8%或19.7百萬港元將用于擴大我們華南及華東的分銷網絡; 3、約10.2%或12.0百萬港元將用于提高品牌知名度,方法為媒體營銷及推廣; 4、約19.9%或23.4百萬港元將用于進一步加大研發力度、采購質量管理設備及 擴大產品組合,長遠而言為業務增值; 5、約3.4%或4.0百萬港元將用于升級IT系統; 6、約5.7%或6.6百萬港元將撥作營運資金及用作其他一般公司用途。

Underwriting Syndicate

Sole Sponsor (1)
Soochow Securities International Capital Limited CE BBG379
Overall Coordinators (2)
东吴证券国际经纪有限公司 CE AYA587 CS Wealth Securities Limited CE AAD244
Joint Bookrunners (8)
东吴证券国际经纪有限公司 CE AYA587 CS Wealth Securities Limited CE AAD244 SPDB International Capital Limited CE BFZ375 交银国际证券有限公司 CE APJ121 YUE XIU SECURITIES COMPANY LIMITED CE ABQ722 SHANXI SECURITIES INTERNATIONAL LIMITED CE BEM330 SHENWAN HONGYUAN SECURITIES (H.K.) LIMITED CE AAC927 Apricot Capital (Hong Kong) Limited CE ACX624
Joint Lead Managers (13)
东吴证券国际经纪有限公司 CE AYA587 CS Wealth Securities Limited CE AAD244 SPDB International Capital Limited CE BFZ375 交银国际证券有限公司 CE APJ121 YUE XIU SECURITIES COMPANY LIMITED CE ABQ722 SHANXI SECURITIES INTERNATIONAL LIMITED CE BEM330 SHENWAN HONGYUAN SECURITIES (H.K.) LIMITED CE AAC927 Apricot Capital (Hong Kong) Limited CE ACX624 ZMF Asset Management Limited CE AWF641 DL SECURITIES (HK) LIMITED CE AZN279 FORTHRIGHT SECURITIES COMPANY LIMITED CE BGP713 CNI Securities Group Limited CE ATM582 MASTERLINK SECURITIES (HONG KONG) CORPORATION LIMITED CE ACS304

Cornerstone Investors

This stock has no cornerstone investors.

Directors & Management

PositionChinese nameEnglish Name
Chairman謝偉—
Company Secretary劉靜詩—
No director data available.

Major Shareholders

Major Shareholders & Holdings現代生物科技(由謝先生全資擁有)持有450,000,000股股份,佔緊隨全球發售及資本化發行完成後已發行股本約75%,謝先生被視為持有同等權益。
About this page

This page shows Modern Chi Med (01643) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect